Multiply Labs has reached an settlement with pharmaceutical large AstraZeneca to guage the potential for making use of GMP (Good Manufacturing Practices)-ready robotic methods to commercial-scale cell remedy manufacturing. Multiply Labs is a specialist in autonomous manufacturing know-how for superior therapies.
The collaboration will deal with end-to-end robotic automation of industry-standard devices utilized in cell remedy manufacturing utilizing Multiply Labs’ robotic biomanufacturing system.
The aim is to allow scalable, high-throughput manufacturing whereas sustaining the rigorous high quality and regulatory requirements required for medical and industrial use.
Fred Parietti, PhD, CEO of Multiply Labs, says: “Cell therapies are among the many most promising, but advanced medicines being developed as we speak. Our mission is to make these therapies extra broadly obtainable by growing manufacturing effectivity and scale.
“This settlement with AstraZeneca permits us to guage our multi-arm robotic clusters in a setting the place we are able to mix a number of the world’s greatest scientific and medical experience with our robotic platform to construct the subsequent era of high-throughput, GMP-ready cell remedy manufacturing.”
Multiply Labs’ latest methods use 4 robotic arms working in parallel to run a broad vary of cell remedy manufacturing devices already in use by the {industry}.
This structure minimizes the necessity for course of modifications whereas maximizing output in present services, focusing on increased productiveness.
